# Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

> **NCT02588170** · PHASE3 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 219 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Surufatinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02588170
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-07
- **Primary completion:** 2019-03-31
- **Final completion:** 2022-07-07
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588170, "Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02588170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*